Company / R&D Expense
LENZ Therapeutics, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$18.7M
FY2025
5-year range
$18.7M / $72.8M
FY2021-FY2025
Trend
-37.4%
vs FY2024
Sector context
#199 of 210
Health Care
What the data says
Among 210 Health Care companies, LENZ Therapeutics, Inc. is in the bottom 5% for r&d expense. R&D Expense has declined for 3 consecutive years, from $73M in FY2022 to $19M in FY2025.
Based on SEC 10-K filings.
$19M in FY2025 with a 5-year CAGR of +15.4%.
Declined from $60M to $19M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -36.5%
- 5-Year CAGR
- +15.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 210This company $18.7M Sector average $644.1M
▼
-97.1% below sector average
Key checks
Key Insights
- LENZ Therapeutics, Inc.'s r&d expense has declined for 3 consecutive years.
- 5-year CAGR of +15.4%, indicating consistent growth.
- In FY2025, r&d expense decreased 37.4% year-over-year.
- Ranks #199 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.7M | -37.4% |
| FY2024 | $29.8M | -49.9% |
| FY2023 | $59.5M | -18.2% |
| FY2022 | $72.8M | +91.9% |
| FY2021 | $37.9M | +315.8% |
| FY2020 | $9.1M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026